211At-HuBC8-B10

211At-HuBC8-B10 is a CD45-directed radioimmunotherapy (RIT) consisting of a humanized monoclonal antibody (HuBC8) conjugated to the alpha-emitting radionuclide astatine-211 (211At) via a boron cage linker (B10). It is being developed as a targeted conditioning agent to ablate bone marrow-resident hematopoietic stem cells (HSPCs) prior to autologous hematopoietic stem cell transplantation (HCT) or gene therapy. By targeting CD45, which is expressed exclusively on hematopoietic cells, the drug aims to provide efficient myeloablation with reduced non-hematologic toxicity compared to traditional conditioning agents like busulfan or total body irradiation (TBI). Preclinical studies in nonhuman primates have demonstrated its ability to enable stable long-term engraftment of gene-edited stem cells with minimal adverse reactions.

Other names

astatine-211-labeled humanized BC8 antibodyastatine211-labeled humanized BC8 antibodyastatine 211-labeled humanized BC8 antibodyCD45-targeted alpha-radioimmunotherapyCD-45-targeted alpha-radioimmunotherapyCD 45-targeted alpha-radioimmunotherapy